Activité biologique And NotT. Di Paolo
List of bibliographic references
Number of relevant bibliographic references: 21.| Ident. | Authors (with country if any) | Title |
|---|---|---|
| 000487 | David Maltete [France] ; Thibault Edouard [France] ; Bruno Mihout [France] ; Jean Costentin [France] | Increased erythrocyte catechol-O-methyltransferase activity in elderly: relationship to clinical peculiarities in Parkinson's disease? |
| 000753 | C. Cavin [Suisse] ; M. Marin-Kuan [Suisse] ; S. Langouët [France] ; C. Bezencon [Suisse] ; G. Guignard [Suisse] ; C. Verguet [Suisse] ; D. Piguet [Suisse] ; D. Holzh User [Suisse] ; R. Cornaz [Suisse] ; B. Schilter [Suisse] | Induction of Nrf2-mediated cellular defenses and alteration of phase I activities as mechanisms of chemoprotective effects of coffee in the liver |
| 000845 | Pauline Sibille [France] ; Sébastien Lopez [France] ; Isabelle Brabet [France] ; Omella Valenti [États-Unis] ; Nadia Oueslati [France] ; Florence Gaven [France] ; Cyril Goudet [France] ; Hugues-Olivier Bertrand [France] ; Jacques Neyton [France] ; Michael J. Marino [États-Unis] ; Marianne Amalric [France] ; Jean-Philippe Pin [France] ; Francine C. Acher [France] | Synthesis and biological evaluation of 1 -amino -2 -phosphonomethylcyclopropanecarboxylic acids, new group III metabotropic glutamate receptor agonists |
| 000B11 | Marina Mapelli [Italie] ; Lucia Massimiliano [Italie] ; Claudia Crovace [Italie, États-Unis] ; Markus A. Seeliger [États-Unis] ; Li-Huei Tsai [France] ; Laurent Meijer [France] ; Andrea Musacchio [Italie] | Mechanism of CDK5/p25 binding by CDK inhibitors |
| 000F13 | Wakako Maruyama [Japon] ; Yukihiro Akao [Japon] ; Maria Chrisina Carrillo [Argentine] ; Ken-Ichi Kitani [Japon] ; Moussa B. H. Youdium [Israël] ; Makoto Naoi [Japon] | Neuroprotection by propargylamines in Parkinson's disease: Suppression of apoptosis and induction of prosurvival genes |
| 000F30 | H. E. Junginger [Pays-Bas] | Iontophoretic delivery of apomorphine: from in-vitro modelling to the Parkinson patient |
| 001026 | Jaime Sanabria [Espagne] ; Pedro Garcia Ruiz [Espagne] ; Raimundo Gutierrez [Espagne] ; Francisco Marquez [Espagne] ; Paloma Escobar [Espagne] ; Michele Gentil [France] ; Carlos Cenjor [Espagne] | The effect of levodopa on vocal function in Parkinson's disease |
| 001098 | Pharmacologie des récepteurs métabotropiques du glutamate Implication dans la douleur | |
| 001172 | L. A. Smith [Royaume-Uni] ; M. G. Jackson [Royaume-Uni] ; C. Bonhomme [France] ; C. Chezaubernard [France] ; K. B. Pearce [Royaume-Uni] ; P. Jenner [Royaume-Uni] | Transdermal administration of piribedil reverses MPTP-induced motor deficits in the common marmoset |
| 001175 | A. Boireau [France] ; P. Dubedat [France] ; F. Bordier [France] ; A. Imperato [France] ; S. Moussaoui [France] | The protective effect of riluzole in the MPTP model of Parkinson's disease in mice is not due to a decrease in MPP+ accumulation |
| 001242 | D. C. Rogers [Royaume-Uni] ; B. Costall [Royaume-Uni] ; A. M. Domeney [France] ; P. A. Gerrard [Royaume-Uni] ; M. Greener [Royaume-Uni] ; M. E. Kelly [Royaume-Uni] ; J. J. Hagan [Royaume-Uni] ; A. J. Hunter [Royaume-Uni] | Anxiolytic profile of ropinirole in the rat, mouse and common marmoset |
| 001321 | W. Koek [France] | N-methyl-D-aspartate antagonists and drug discrimination |
| 001345 | E. Bezard [France] ; C. Brefel [France] ; F. Tison [France] ; H. Peyro-Saint-Paul [France] ; P. Ladure [France] ; O. Rascol [France] ; C. E. Gross [France] | Effect of the α2 adrenoreceptor antagonist, idazoxan, on motor disabilities in mptp-treated monkey |
| 001351 | F. A. Dajas-Bailador [Uruguay] ; M. Asencio [Chili] ; C. Bonilla [Uruguay] ; M. C. Scorza [Uruguay] ; C. Echeverry [Uruguay] ; M. Reyes-Parada [Uruguay] ; R. Silveira [Uruguay] ; P. Protais [France] ; G. Russell [Nouvelle-Zélande] ; B. K. Cassels [Chili] ; F. Dajas [Uruguay] | Dopaminergic pharmacology and antioxidant properties of pukateine, a natural product lead for the design of agents increasing dopamine neurotransmission |
| 001428 | A. Boireau [France] ; M. Meunier [France] ; A. Imperato [France] | Ouabain-induced increase in dopamine release from mouse striatal slices is antagonized by riluzole |
| 001433 | E. X. Albuquerque [États-Unis, Brésil] ; E. F. R. Pereira [États-Unis] ; M. F. M. Braga [États-Unis, Brésil] ; H. Matsubayashi [États-Unis] ; M. Alkondon [États-Unis] | Neuronal nicotinic receptors modulate synaptic function in the hippocampus and are sensitive to blockade by the convulsant strychnine and by the anti-Parkinson drug amantadine |
| 001448 | J. L. Montastruc [France] ; M. Pelat [France] ; P. Verwaerde [France] ; C. Brefel-Courbon [France] ; M. A. Tran [France] ; O. Blin [France] ; O. Rascol [France] ; J. M. Senard [France] | Fluoxetine in orthostatic hypotension of Parkinson's disease : A clinical and experimental pilot study |
| 001455 | L. Fauchier [France] ; D. Babuty [France] ; M. L. Autret [France] ; P. Poret [France] ; P. Cosnay [France] ; J. P. Fauchier [France] | Effect of flecainide on heart rate variability in subjects without coronary artery disease or congestive heart failure |
| 001660 | M. Spedding [France] ; M. Williams [États-Unis] | Developments in purine and pyridimidine receptor-based therapeutics |
| 001975 | R. Nordmann [France] ; C. Ribiere | Superoxyde dismutases : rôle biologique : espoir thérapeutique ? |
| 001A31 | H. Allain ; D. Bentueê-Ferrer ; J. L. Merot ; R. Decombe | Pharmacologie des agonistes dopaminergiques |
| This area was generated with Dilib version V0.6.29. |  |